Comparison of Blood and Urine Profiles of Remogliflozin in Rat PK Study Using a Single and Simple UPLC Method
Published: 2023-05-13
Page: 53-63
Issue: 2023 - Volume 6 [Issue 1]
G. K. Aiswarya
National College of Pharmacy, KMCT Group of Institutions, Manassery, Kozhikode-673602, Kerala, India.
P. C. Indukala
National College of Pharmacy, KMCT Group of Institutions, Manassery, Kozhikode-673602, Kerala, India.
S. Kathirvel
National College of Pharmacy, KMCT Group of Institutions, Manassery, Kozhikode-673602, Kerala, India.
K. Raja Rajeswari *
Department of Pharmaceutical Analysis, Sri Sivani College of Pharmacy, Srikakulam-532 402, Andhra Pradesh, India.
*Author to whom correspondence should be addressed.
Abstract
This study describes a comparison between blood and urine profiles of Remogliflozin simultaneously in a rat pharmacokinetic study using a simple UPLC method. Quantitative determination of Remogliflozin is performed in rat blood with the recovery values in the range of 85-115%. A reversed phase Ultra-performance liquid chromatography (UPLC) with UV detector is used. The method utilizes an Acquity UPLC CSH Fluoro-Phenyl column (150x1mm, 1.7 µm) and a gradient elution with mobile phase consisting of acetonitrile and 0.1% formic acid (15:85) at a flow rate of 0.8 mL min-1. The method adequately resolves the analyte and internal standard (metformin) within a run time of 5 min. The UV detection carried out at 275 nm. In both blood and urine, the detection limit of Remogliflozin is found to be 2 µg mL-1 and the LOQ as 10 µg mL-1. Two profiles were compared by conducting single oral dose in vivo rat PK study after complete validation of the UPLC method.
Keywords: Antidiabetic, remogliflozin, pharmacokinetics, UPLC, rat blood and Urine